Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint
- 916 Downloads
A cross-over controlled administration study of smoked cannabis was carried out on occasional and heavy smokers. The participants smoked a joint (11 % Δ9-tetrahydrocannabinol (THC)) or a matching placebo on two different occasions. Whole blood (WB) and oral fluid (OF) samples were collected before and up to 3.5 h after smoking the joints. Pharmacokinetic analyses were obtained from these data. Questionnaires assessing the subjective effects were administered to the subjects during each session before and after the smoking time period. THC, 11-hydroxy-THC (11-OH-THC) and 11-nor-9-carboxy-THC (THCCOOH) were analyzed in the blood by gas chromatography or liquid chromatography (LC)-tandem mass spectrometry (MS/MS). The determination of THC, THCCOOH, cannabinol (CBN), and Δ9-tetrahydrocannabinolic acid A (THC-A) was carried out on OF only using LC-MS/MS. In line with the widely accepted assumption that cannabis smoking results in a strong contamination of the oral cavity, we found that THC, and also THC-A, shows a sharp, high concentration peak just after smoking, with a rapid decrease in these levels within 3 h. No obvious differences were found between both groups concerning THC median maximum concentrations measured either in blood or in OF; these levels were equal to 1,338 and 1,041 μg/L in OF and to 82 and 94 μg/L in WB for occasional and heavy smokers, respectively. The initial WB THCCOOH concentration was much higher in regular smokers than in occasional users. Compared with the occasional smokers, the sensation of confusion felt by the regular smokers was much less while the feeling of intoxication remained almost unchanged.
KeywordsCannabis Pharmacokinetic Oral fluid Whole blood Heavy use Occasional use
The authors would like to thank the Swiss National Science Foundation (FNS_320030_127507/1), the Centre d’Imagerie BioMédicale (CIBM), and the Faculty of Biology and Medicine (interdisciplinary grant) at the University of Lausanne for their financial support. We thank Dr. Marc Augsburger, Dr. Christian Staub, and Prof. Patrice Mangin of the University Center of Legal Medicine Lausanne-Geneva; Dr Jean-Frédéric Mall of the Department of Psychiatry at CHUV; Prof. Thierry Buclin; and the staff of the division of Clinical Pharmacology and Toxicology at CHUV. The authors would also like to thank Ms. Ann Travis and Fiona Smith for reviewing the English version of the text.
- 2.Menetrey A, Augsburger M, Giroud C, Mangin P (2001) Cannabis and automobile driving. Praxis 90(34):1398–1407Google Scholar
- 7.Daldrup T, Käferstein H, Köhler H, Maier R, Musshoff F (2000) Deciding between one off/occasional and regular cannabis consumption. Blutalkohol 37(1):39–47Google Scholar
- 9.Perez-Reyes M (1990) Marijuana smoking: factors that influence the bioavailability of tetrahydrocannabinol. NIDA Res Monogr 99:42–62Google Scholar
- 12.Laloup M, Del Mar Ramirez Fernandez M, Wood M, De Boeck G, Maes V, Samyn N (2006) Correlation of Delta9-tetrahydrocannabinol concentrations determined by LC-MS-MS in oral fluid and plasma from impaired drivers and evaluation of the on-site Drager DrugTest. Forensic Sci Int 161(2–3):175–179. doi: 10.1016/j.forsciint.2006.03.033 Google Scholar
- 16.Brenneisen R, Meyer P, Chtioui H, Saugy M, Kamber M (2010) Plasma and urine profiles of Delta9-tetrahydrocannabinol and its metabolites 11-hydroxy-Delta9-tetrahydrocannabinol and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Anal Bioanal Chem 396(7):2493–2502. doi: 10.1007/s00216-009-3431-3 CrossRefGoogle Scholar
- 17.Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, Woodcock H, Dorward P, Pigliacampo B, Close S, Platt B, Riedel G (2012) Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta(9)-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology 219(3):859–873. doi: 10.1007/s00213-011-2415-0 CrossRefGoogle Scholar
- 19.Schwilke EW, Schwope DM, Karschner EL, Lowe RH, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA (2009) Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin Chem 55(12):2180–2189. doi: 10.1373/clinchem.2008.122119 CrossRefGoogle Scholar
- 20.Schwope DM, Karschner EL, Gorelick DA, Huestis MA (2011) Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 57(10):1406–1414. doi: 10.1373/clinchem.2011.171777 CrossRefGoogle Scholar
- 24.Milman G, Schwope DM, Schwilke EW, Darwin WD, Kelly DL, Goodwin RS, Gorelick DA, Huestis MA (2011) Oral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Delta(9)-tetrahydrocannabinol administration. Clin Chem 57(11):1597–1606. doi: 10.1373/clinchem.2011.169490 CrossRefGoogle Scholar
- 26.Battistella G, Fornari E, Thomas A, Mall JF, Chtioui H, Appenzeller M, Annoni JM, Favrat B, Maeder P, Giroud C (2013) Weed or wheel! FMRI, behavioural, and toxicological investigations of how cannabis smoking affects skills necessary for driving. PloS one 8(1):e52545. doi: 10.1371/journal.pone.0052545 CrossRefGoogle Scholar
- 27.Muntendam R, Happyana N, Erkelens T, Bruining F, Kayser O (2012) Time dependant metabolomics and transcriptional analysis of cannabinoid biosynthesis in Cannabis sativa var Bedrobinol and Bediol grown under standardized condition and with genetic homogeneity. Online Int J Med Plants Res 1(2):31–40Google Scholar